Human GLP-1(Glucagon Like Peptide 1) ELISA Kit (E-EL-H6025)

This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human GLP-1. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human GLP-1 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human GLP-1, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human GLP-1. You can calculate the concentration of Human GLP-1 in the samples by comparing the OD of the samples to the standard curve.

Glucagon-like peptide 1 (GLP-1) is an incretin hormone generated by prohormone convertase-mediated cleavage of proglucagon in enteroendocrine L cells of the distal small intestine and colon. Nutrient intake triggers secretion within minutes, and the biologically active forms are GLP-1(7-37) and its amidated counterpart GLP-1(7-36) amide, both rapidly inactivated by dipeptidyl peptidase-4. Activation of the G protein-coupled GLP-1 receptor elevates cyclic AMP and engages protein kinase A and EPAC2, producing glucose-dependent stimulation of insulin biosynthesis and secretion from pancreatic beta cells and suppression of glucagon release. The hormone also delays gastric emptying, reduces intestinal motility and promotes satiety through vagal afferent and hypothalamic circuits, thereby coupling meal handling to glucose disposal while limiting the risk of hypoglycemia. Because native GLP-1 is very short-lived, degradation-resistant receptor agonists and inhibitors of its inactivating peptidase have been developed and are now important therapeutics for type 2 diabetes and obesity. This ELISA kit enables quantitative determination of GLP-1, and measurement of the hormone supports research on incretin physiology, glucose regulation and metabolic disease, in which it plays a key role in postprandial glucose control.